Full Separator
Our laboratory has developed dendrimer-based delivery platforms to transform how macromolecules and biologics are deployed against some of the most devastating neurological and ophthalmic disorders. By leveraging the unique architecture and modularity of dendrimers, we have engineered versatile systems capable preserving the extracellular activity of biologics while ensuring targeted delivery into target cells (adding new mechanism of action).
Through novel and innovative synthetic strategies combined with advanced analytical techniques, we have developed and characterized a broad range of dendrimer–biologic conjugates, including:
- Dendrimer-antibody conjugates, which merge the targeting specificity of antibodies with the nanoscale trafficking precision of dendrimers.
- Dendrimer–peptide conjugates, offering stable, bioactive delivery for signaling modulation and receptor targeting.
- Dendrimer–RNA therapeutics, including siRNA, microRNA, and antisense oligonucleotide (ASO) conjugates, enabling potent, sequence-specific modulation of gene expression while overcoming degradation and uptake barriers.
- Dendrimer–Cas9 conjugates, representing a non-viral, neuron-accessible platform for CRISPR-based gene editing in vivo.
